About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Cardiovascular Diseases group is a translational research group within the Cardiology Department of Vall d’Hebron Hospital that performs laboratory, clinical and epidemiological research. In the CIBERCV network we are within the topic of descriptor 2 “Arterial disease, thrombosis and myocardial ischemia-reperfusion injury”. Our contributions in these topics address the following lines:
In the CIBERESP network, our group is interested in the study of effectiveness/cost-effectiveness of cardiovascular interventions, health outcome research and methods in clinical research. The group has 19 principal investigators, 32 active projects and clinical trial and has been done 142 publications in 2020.
PMID: 33642036 Journal: MEDICINA CLINICA Year: 2021 Reference: Med Clin (Barc). 2021 May 21;156(10):496-499. doi: 10.1016/j.medcli.2020.12.005. Epub 2021 Feb 26. Impact factor: 1.725 Publication type: Letter or abstract Authors: Francisco-Pascual, Jaume, Rivas-Gandara, Nuria, Santos-Ortega, Alba, Perez-Rodon, Jordi, Benito, Begona, Belahnech, Yassin, Ferreira-Gonzalez, Ignacio et al. DOI: 10.1016/j.medcli.2020.12.005
PMID: 32616434 Journal: REVISTA ESPANOLA DE CARDIOLOGIA Year: 2021 Reference: Rev Esp Cardiol. 2021 Mar;74(3):216-224. doi: 10.1016/j.rec.2020.03.026. Epub 2020 Jun 29. Impact factor: 4.753 Publication type: Paper in national publication Authors: Diez-Lopez, Carles, Barriales-Villa, Roberto, Ochoa, Juan P, Larranaga-Moreira, Jose M, Salazar-Mendiguchia, Joel, Garcia-Pavia, Pablo, Ortiz-Genga, Martin, Monserrat, Lorenzo, Ripoll-Vera, Tomas, Zorio, Esther et al. DOI: 10.1016/j.rec.2020.03.026
PMID: 32499017 Journal: REVISTA ESPANOLA DE CARDIOLOGIA Year: 2021 Reference: Rev Esp Cardiol. 2021 Mar;74(3):257-262. doi: 10.1016/j.rec.2020.02.015. Epub 2020 Jun 1. Impact factor: 4.753 Publication type: Paper in national publication Authors: Evangelista, Arturo, Barrabes, Jose A, Lidon, Rosa-Maria, Rodriguez-Lecoq, Rafael, Maeso, Jordi, Bellmunt, Sergi, Lopez-Sainz, Angela, Sureda, Carlos, Teixido-Tura, Gisela, Gonzalez-Alujas, Teresa et al. DOI: 10.1016/j.rec.2020.02.015
PMID: 33637474 Journal: REVISTA ESPANOLA DE CARDIOLOGIA Year: 2021 Reference: Rev Esp Cardiol (Engl Ed). 2021 Jul;74(7):626-628. doi: 10.1016/j.rec.2020.12.012. Epub 2021 Feb 23. Impact factor: 4.753 Publication type: Letter whit IF Authors: Azpiroz-Franch, Maria Josefa, Rello-Sabate, Pau, Oristrell-Santamaria, Gerard, Gonzalez-Alujas, Teresa, Marti-Aguasca, Gerard, Soriano-Colome, Toni et al. DOI: 10.1016/j.rec.2020.12.012
The consensus document is the result of multidisciplinary work that takes into account the risks associated with all stages of women's lives and the differences compared to men.
The study, which involved Vall d'Hebron, developed an action plan to efficiently allocate resources to patients most at risk of suffering this complication.
In light of this evidence, hospitals such as Vall d'Hebron have already started to include warnings about environmental pollution in their hospital discharge plans after a myocardial infarction.
